Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, announced details of a poster presentation on the induction of a systemic immune response with intralesional PV-10 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.
http://www.businesswire.com/news/topix/20130410006143/en
http://www.businesswire.com/news/topix/20130410006143/en
No comments:
Post a Comment